两例肾移植患者头部晚期皮肤鳞状细胞癌接受西米普利单抗治疗
实体器官移植受者发生皮肤鳞状细胞癌(cSCC)的风险为一般人群的65-250倍,且病程更具侵袭性。本文报告两例肾移植患者头部难治性晚期cSCC,接受免疫检查点抑制剂西米普利单抗治疗。
要点
- 器官移植受者cSCC风险为一般人群65-250倍,病程更具侵袭性。
- 早期cSCC可通过简单切除有效治疗,晚期则预后差。
- 免疫检查点抑制剂西米普利单抗用于两例肾移植患者难治性cSCC。
核心结论
- 本文报告两例肾移植患者头部难治性晚期cSCC接受西米普利单抗治疗。
研究设计与样本
- 病例报告,两例肾移植患者。
主要发现
- 实体器官移植受者发生cSCC的可能性为一般人群的65-250倍(Am J Transplant 2017; 17: 2509)。
- 移植受者中cSCC病程更具侵袭性。
- 早期cSCC可通过简单切除轻松有效治疗,晚期则预后差。
临床怎么用
- 原文指出密切随访和皮肤科医生定期皮肤检查对这类患者的管理至关重要。
- 原文指出免疫检查点抑制剂已被证明可有效实现长期缓解。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It is well known that organ transplant recipients are prone to develop non-melanoma skin cancers, particularly cutaneous squamous cell carcinoma (cSCC). This is explained by the long-term use of immunosuppressants and thus the decrease of the immunosurveillance that protects from developing malignant tumours. Solid organ transplant recipients (SOTRs) are 65-250 times more likely to develop cSCC compared to the general population (Am J Transplant 2017; 17: 2509). Moreover, in these patients cSCCs follow a more aggressive course. Close follow-up and regular skin check-ups by a dermatologist are, therefore, crucial in the management of these patients. When detected early, cSCC can be easily and effectively treated by a simple excision. However, when advanced, outcomes are poor. Immune checkpoints inhibitors (ICIs) have been recently added to our arsenal and represent a breakthrough, having proved to be effective in achieving long-term responses. We, hereby, present two cases of difficult-to-treat cSCCs in renal transplanted patients.
引用
- Orte Cano C, Van Meerhaeghe T, Tannous J, et al. Advanced cutaneous squamous cell carcinoma of the head in two renal transplanted patients treated with cemiplimab. J Eur Acad Dermatol Venereol. 2022. PMID: 34855244. doi:10.1111/jdv.17658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。